GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$56.69
0.70 (1.25%)
▲
5d:
+5.1%
30d:
-0.25%
90d:
+15.6%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 29, 2026
26d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$74.15
Based on 5.8% avg growth
INTRINSIC VALUE TODAY
$46.04
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $56.69, which is considered fair relative to its 30-day fair value range of $52.94 to $57.56. The stock's valuation (Forward PE: 10.9) is in line with its historical norms (10.9). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GSK is in a strong uptrend. The price is approaching resistance at $55.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a strong uptrend. The price is approaching resistance at $55.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$52.94 -
$57.56
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($57.48)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$52.94 -
$57.56
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$51.55
Resistance Level
$55.98
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.91
Wall Street Target
$57.48
(+2.7%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
54.7%
Profit Margin
17.5%
Valuation Premium vs History
+0.2% premium
PE vs Historical
10.9 vs 10.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$56.10
(+0%)
2-Year Target
$56.21
(+0%)
3-Year Target
$56.33
(+1%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$56.29
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.6%)
$142.89
(+155%)
Base:
(SPY PE: 10.9, Growth: 7.6%)
$69.73
(+25%)
Bear:
(PE: 9.3, Growth: 7.6%)
$59.27
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 14.09 | Current EPS (TTM): $3.68
Bull Case
$79.55
(+53%)
Analyst growth 39.5%, PE expands to 15.5
Base Case
$72.31
(+39%)
Market implied 39.5%, PE stable at 14.1
Bear Case
$35.25
(-32%)
Severe decline -20.0%, PE contracts to 12.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 02, 2026 10:53 AM ET
Data refreshes hourly during market hours. Next update: 11:53 AM
Data refreshes hourly during market hours. Next update: 11:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Plc Gsk
BUY
1470000 shares
2025-12-11
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 58 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 57 HOLD |
